Treadmill exercise alleviates diabetic cardiomyopathy by suppressing plasminogen activator inhibitor expression and enhancing eNOS in streptozotocin-induced male diabetic rats

Endocrine Connections

Volumn 7, Issue 4, 2018, Pages 553-559

  Chengji, Wang ^a   Xianjin, Fan ^a  

^a CHAOHU UNIVERSITY   (China)

Author keywords

Diabetic cardiomyopathy; Different intensity; Exercises; Nitric oxide; PAI 1

Indexed keywords

DIACYLGLYCEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED PROTEIN; INSULIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; VON WILLEBRAND FACTOR;

AEROBIC EXERCISE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE INTENSITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; INSULIN RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREADMILL EXERCISE;

EID: 85046461972     PISSN: None     EISSN: 20493614     Source Type: Journal    
DOI: 10.1530/EC-18-0060     Document Type: Article

References (41)

1. Willi C, Bodenmann P, Ghali WA, Faris PD & Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007 298 2654-2664. (https://doi.org/10.1001/jama.298.22.2654)
2. Hu FB, Li TY, Colditz GA, Willett WC & Manson JE. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 2003 289 1785-1791. (https://doi.org/10.1001/jama.289.14.1785)
3. Norberg M, Stenlund H, Lindahl B, Andersson C, Weinehall L, Hallmans G & Eriksson JW. Components of metabolic syndrome predicting diabetes: no role of inflammation or dyslipidemia. Obesity 2007 15 1875-1885. (https://doi.org/10.1038/oby.2007.222)
4. Meigs JB. Epidemiology of the insulin resistance syndrome. Current Diabetes Reports 2003 3 73-79. (https://doi.org/10.1007/s11892-003-0057-2)
5. Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP & van der Poll T. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006 55 1807-1812. (https://doi.org/10.2337/db05-1543)
6. Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC & Hoekstra JB. Hyperglycemia: a prothrombotic factor? Journal of Thrombosis and Haemostasis 2010 8 1663-1669. (https://doi.org/10.1111/j.1538-7836.2010.03910.x)
7. Carr ME. Diabetes mellitus: a hypercoagulable state. Journal of Diabetes and its Complications 2001 15 44-54. (https://doi.org/10.1016/S1056-8727(00)00132-X)
8. Petrauskiene V, Falk M, Waernbaum I, Norberg M & Eriksson JW. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005 48 1017-1021. (https://doi.org/10.1007/s00125-005-1715-5)
9. Jax TW, Peters AJ, Plehn G & Schoebel FC. Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes-a two year follow-up of 243 patients. Cardiovascular Diabetology 2009 8 48. (https://doi.org/10.1186/1475-2840-8-48)
10. American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care 2000 23 (Supplement 1) S27-S31. (https://doi.org/10.2337/diacare.26.2007.S28)
11. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine 2012 367 319-328. (https://doi.org/10.1056/NEJMoa1203858)
12. Eliasson MC, Jansson JH, Lindahl B & Stegmayr B. High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovascular Diabetology 2003 2 19. (https://doi.org/10.1186/1475-2840-2-19)
13. Wannamethee SG, Sattar N, Rumley A, Whincup PH, Lennon L & Lowe GD. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care 2008 31 995-1000. (https://doi.org/10.2337/dc07-1569)
14. Heldgaard PE, Henriksen JE, Sidelmann JJ, de Fine Olivarius N, Siersma VD & Gram JB. Similar cardiovascular risk factor profile in screen-detected and known type 2 diabetic subjects. Scandinavian Journal of Primary Health Care 2011 29 85-91. (https://doi.org/10.3109/02813432.2011.565164)
15. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003 108 420-425. (https://doi.org/10.1161/01.CIR.0000080884.27358.49)
16. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F & Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT study group. European concerted action on thrombosis and disabilities. Circulation 1996 94 2057-2063. (https://doi.org/10.1161/01.CIR.94.9.2057)
17. Eliasson M, Evrin PE & Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. Journal of Clinical Epidemiology 1994 47 513-524. (https://doi.org/10.1016/0895-4356(94)90298-4)
18. Festa A, D’Agostino R Jr, Tracy RP & Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes 2002 51 1131-1137. (https://doi.org/10.2337/diabetes.51.4.1131)
19. Festa A, Williams K, Tracy RP, Wagenknecht LE & Haffner SM. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006 113 1753-1759. (https://doi.org/10.1161/CIRCULATIONAHA.106.616177)
20. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. American Journal of Cardiology 2003 92 18J-26J. (https://doi.org/10.1016/S0002-9149(03)00612-X)
21. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B & Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the developmentof a first stroke. Stroke 2000 31 26-32. (https://doi.org/10.1161/01.STR.31.1.26)
22. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A & de Faire U. Plasma levels of tissue plasminogen activator/ plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 2019-2023. (https://doi.org/10.1161/01.ATV.20.8.2019)
23. Frankel DS, Meigs JB, Massaro JM, Wilson PW, O’Donnell CJ, D’Agostino RB & Tofler GH. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation 2008 118 2533-2539. (https://doi.org/10.1161/CIRCULATIONAHA.108.792986)
24. Kerr R, Stirling D & Ludlam CA. Interleukin 6 and haemostasis. British Journal of Haematology 2001 115 3-12. (https://doi.org/10.1046/j.1365-2141.2001.03061.x)
25. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H & Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003 361 226-228. (https://doi.org/10.1016/S0140-6736(03)12255-6)
26. Way KJ, Katai N & King GL. Protein kinase C and the development of diabetic vascular complications. Diabetic Medicine 2001 18 945-959. (https://doi.org/10.1046/j.0742-3071.2001.00638.x)
27. Aly YE, Abdou AS, Rashad MM & Nassef MM. Effect of exercise on serum vitamin D and tissue vitamin D receptors in experimentally induced type 2 diabetes mellitus. Journal of Advanced Research 2016 7 671-679. (https://doi.org/10.1016/j.jare.2016.07.001)
28. Delevatti RS, Pinho CD, Kanitz AC, Alberton CL, Marson EC, Bregagnol LP, Lisboa SC, Schaan BD & Kruel LF. Glycemic reductions following water-and land-based exercise in patients with type 2 diabetes mellitus. Complementary Therapies in Clinical Practice 2016 24 73-77. (https://doi.org/10.1016/j.ctcp.2016.05.008)
29. Meyer JD, Koltyn KF, Stegner AJ, Kim JS & Cook DB. Influence of exercise intensity for improving depressed mood in depression: a dose-response study. Behavior Therapy 2016 47 527-537. (https://doi.org/10.1016/j.beth.2016.04.003)
30. Dellas C & Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thrombosis and Haemostasis 2005 93 631-640. (https://doi.org/10.1160/TH05-01-0033)
31. Sand KL, Flatebo T, Andersen MB & Maghazachi AA. Effects of exercise on leukocytosis and blood hemostasis in 800 healthy young females and males. World Journal of Experimental Medicine 2013 3 11-20. (https://doi.org/10.5493/wjem.v3.i1.11)
32. Kahraman S, Bediz CS, Pişkin O, Aksu I, Topçu A, Yüksel F & Demirkan F. The effect of the acute submaximal exercise on thrombin activatable fibrinolysis inhibitor levels in young sedentary males. Clinical and Applied Thrombosis/Hemostasis 2011 17 414-420. (https://doi.org/10.1177/1076029610385672)
33. Hilberg T, Nowacki PE, Muller-berghaus G & Gabriel HH. Changes in blood coagulation and fibrinolysis associated with maximal exercise and physical conditioning in women taking low dose oral contraceptives. Journal of Science and Medicine in Sport 2000 3 383-390. (https://doi.org/10.1016/S1440-2440(00)80005-5)
34. Wang JS, Li YS, Chen JC & Chen YW. Effects of exercise training and deconditioning on platelet aggregation induced by alternating shear stress in men. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 454-446. (https://doi.org/10.1161/01.ATV.0000151987.04607.24)
35. Kim HR, Gallant C & Morgan KG. Regulation of PKC autophosphorylation by calponin in contractile vascular smooth muscle tissue. BioMed Research International 2013 2013 358-643. (https://doi.org/10.1155/2013/310461)
36. Kizub IV, Klymenko KI & Soloviev AI. Protein kinase C in enhanced vascular tone in diabetes mellitus. International Journal of Cardiology 2014 174 230-242. (https://doi.org/10.1016/j.ijcard.2014.04.117)
37. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W & King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. PNAS 1992 89 11059-11063. (https://doi.org/10.1073/pnas.89.22.11059)
38. Clarke M & Dodson PM. PKC inhibition and diabetic microvascular complications. Best Practice and Research: Clinical Endocrinology and Metabolism 2007 21 573-586. (https://doi.org/10.1016/j.beem.2007.09.007)
39. Kleindienst A, Battault S, Belaidi E, Tanguy S, Rosselin M, Boulghobra D, Meyer G, Gayrard S, Walther G, Geny B, et al. Exercise does not activate the β3 adrenergic receptor-eNOS pathway, but reduces inducible NOS expression to protect the heart of obese diabetic mice. Basic Research in Cardiology 2016 111 40. (https://doi.org/10.1007/s00395-016-0559-0)
40. Gjovaag T, Hjelmeland AK, Oygard JB, Vikne H & Mirtaheri P. Acute hemodynamic and cardiovascular responses following resistance exercise to voluntary exhaustion. Effects of different loadings and exercise durations. Journal of Sports Medicine and Physical Fitness 2016 56 616-623.
41. Archana R & Mukilan R. Beneficial effect of preferential music on exercise induced changes in heart rate variability. Journal of Clinical and Diagnostic Research 2016 10 CC09-CC11.